| Literature DB >> 27610159 |
Wei Chen1, Weixiong Chen1, Jinshui Zhu1, Niwei Chen1, Yunmin Lu1.
Abstract
The purpose of the current study was to evaluate the anti-inflammatory activity of tetramethlpyrazine on oxazolone-induced colitis mice. Spleen mononuclear cells (SMC), lamina propria mononuclear cells (LPMC) and peripheral blood mononuclear cells (PBMC) were isolated from oxazolone-induced colitis and normal mice. The colitis cells treated by oxazolone were randomly divided into model, low dose, middle dose and high dose groups treated with 0, 0.5, 1.0 and 2.0 g/L tetramethlpyrazine, respectively. The apoptotic rate of SMC and LPMC in the oxazolone-induced group was lower than that in the normal group. Compared with model group, apoptotic rate of SMC was significantly increased in the high dose group, while the apoptotic rate of LPMC in the middle dose group was increased. Compared with SMC, LPMC and PBMC of normal group, the mRNA level of nuclear factor kappa B (NF-kB), transcription factor-activated protein-1 (AP-1) and nuclear factor of activated T cells (NF-AT) were higher in model group. Tetramethylpyrazine inhibited the increase of NF-kB, AP-1 and NF-AT mRNA induced by oxazolone. For SMC, LPMC and PBMC there was significant difference in the mRNA level of AP-1 among the three different doses of tetramethylpyrazine treated groups. However, no significant difference was observed in the mRNA levels of NF-AT and NF-κB between normal and middle groups. Tetramethylpyrazine promoted the apoptotic rate of SMC and LPMC in-vitro, and suppressed the expression of transcription factors in SMC, LPMC and PBMC isolated from oxazolone-induced colitis mice. The study provides a novel insight into the mechanism behind the effect of etramethylpyrazine on colitis.Entities:
Keywords: AP-1; NF-AT; NF-kB; Oxazolone-Induced Colitis; Suppressor; Tetramethlpyrazine
Year: 2016 PMID: 27610159 PMCID: PMC4986104
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Primer sequence and product size of NF-B, AP-1 and NF-AT
| Gene | Primer | Product size (bp) |
|---|---|---|
| GAPDH | Forward: 5' GTCGGTGTGAACGGATTTG 3' | 181 |
| AP-1 | Forward:5’- CCCCACCCAGTTCTTGTGCC -3' | 187 |
| NF-kB | Forward:5’-TTGCCACGCACAGACGGTGT -3' | 192 |
| NF-AT | Forward:5' ACCCTGCCTTTACCCTTC 3' | 227 |
Figure 1Histological examination of colon in the model group under the optical microscope.
Percentage of cell apoptosis after cultivation (%).
| Group | 48 h | 96 h | ||||
|---|---|---|---|---|---|---|
| SMC | LPMC | PBMC | SMC | LPMC | PBMC | |
| Normal | 4.61±1.19 | 4.23±1.01 | 3.97±0.89 | 3.63±0.46 | 4.93±0.71 | 3.60±0.46 |
| Model | 2.89±0.62* | 0.58±0.21** | 2.69±0.92 | 2.52±0.56 | 0.37±0.10 | 3.49±0.36 |
| Low | 3.35±0.26 | 0.58±0.20** | 3.07±0.67 | 3.10±0.81 | 0.69±0.31** | 3.17±0.61 |
| Middle | 3.34±1.00 | 3.96±1.48** | 3.21±0.56 | 2.78±0.45* | 2.94±0.74*## | 3.30±0.59 |
| High | 5.93±1.68* | 1.20±0.51** | 3.08±1.10 | 3.97±0.54# | 1.03±0.35**# | 3.39±0.76 |
Expression level of AP-1 mRNA (10x copies/ml).
| Group | Normal | Model | Low | Middle | High |
|---|---|---|---|---|---|
| SMC | 3.22±0.50 | 5.69±0.69 | 5.21±0.59 | 4.10±0.94 | 4.45±0.33 |
| LPMC | 3.18±0.42 | 5.53±0.95 | 5.20±0.48 | 4.54±0.77 | 4.89±0.24 |
| PBMC | 3.28±0.32 | 5.72±0.49 | 5.22±0.70 | 4.31±0.81# | 4.73±0.35 |
: P < 0.05,
P < 0.01, compared with normal group.
: P < 0.05,
: P < 0.01, compared with model group.
Expression level of NF-κB mRNA (10x copies/ml)
| Group | Normal | Model | Low | Middle | High |
|---|---|---|---|---|---|
| SMC | 3.15±0.69 | 5.71±1.08[ | 4.67±0.44[ | 4.36±0.51 | 4.54±0.36 [ |
| LPMC | 3.06±0.62 | 5.36±0.40 [ | 5.15±0.61 [ | 3.98±0.17 | 4.47±0.87 |
| PBMC | 3.38±0.72 | 5.68±0.76 [ | 4.90±0.37 | 4.04±0.57 | 4.18±0.47[ |
: P < 0.05,
P < 0.01, compare with normal group;
: P < 0.05,
P < 0.01, compare with middle group
: P < 0.05,compare with model group
Expression level of NF-AT mRNA (10x copies/mL)
| Group | Normal | Model | Low | Middle | High |
|---|---|---|---|---|---|
| SMC | 3.65±0.87[ | 5.46±0.58 | 4.96±0.40 | 4.38±0.44 | 4.53±0.35 |
| LPMC | 3.96±0.88 | 5.42±0.85 | 5.09±0.90 | 4.39±0.31 | 4.75±0.44 |
| PBMC | 4.05±0.88 | 5.45±1.00 | 5.11±0.45[ | 4.28±0.28 | 4.75±1.02 |
P < 0.05, compare with model group;
: P < 0.05, compare with middle group
Figure 2Comparison of AP-1 mRNA expressional level in SMC, LPMC and PBMC of normal group, model group and tetramethylpyrazine treated group (low dose, middle dose and high dose
Figure 3Comparison of NF-κB mRNA expressional level in SMC, LPMC and PBMC of normal group, model group and tetramethylpyrazine treated group (low dose, middle dose and high dose
Figure 4Comparison of NF-AT mRNA expressional level in SMC, LPMC and PBMC of normal group, model group and tetramethylpyrazine treated group (low dose, middle dose and high dose